Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene
- PMID: 19463925
- DOI: 10.1016/j.toxlet.2009.05.005
Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene
Abstract
Human cytochrome P450 1B1 (CYP1B1) is found mainly in extrahepatic tissues and is overexpressed in a variety of human tumors. Metabolic activation of 17beta-estradiol (E2) to 4-hydroxy E2 by CYP1B1 has been postulated to be an important factor in mammary carcinogenesis. The inhibition of recombinant human CYP1B1 by 2,2',4,6'-tetramethoxystilbene (TMS) was investigated using either the Escherichia coli membranes of recombinant human CYP1B1 coexpressed with human NADPH-P450 reductase or using purified enzyme. 2,2',4,6'-TMS showed potent and selective inhibition of ethoxyresorufin O-deethylation (EROD) activity of CYP1B1 with IC(50) values of 2 nM. 2,2',4,6'-TMS exhibited 175-fold selectivity for CYP1B1 over CYP1A1 (IC(50), 350 nM) and 85-fold selectivity for CYP1B1 over CYP1A2 (IC(50), 170 nM). However, inhibition of human NADPH-P450 reductase activity by 2,2',4,6'-TMS was negligible. The modes of inhibition by 2,2',4,6'-TMS were noncompetitive for CYP1A1 and CYP1B1. Moreover, 2,2',4,6'-TMS significantly suppressed EROD activity and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced CYP1A1 or CYP1B1 gene expression in human tumor cells such as HepG2 and MCF-10A. Taken together, our results indicate that 2,2',4,6'-TMS is a potently selective inhibitor of human CYP1B1 as well as a suppressor of CYP1B1 expression and may be a valuable tool for determining enzyme properties of human CYP1B1.
Similar articles
-
A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis.Cancer Res. 2001 Nov 15;61(22):8164-70. Cancer Res. 2001. PMID: 11719446
-
Modulation of human cytochrome P450 1B1 expression by 2,4,3',5'-tetramethoxystilbene.Drug Metab Dispos. 2005 Dec;33(12):1771-6. doi: 10.1124/dmd.105.006502. Epub 2005 Aug 24. Drug Metab Dispos. 2005. PMID: 16120791
-
Cytochrome P450 1A1 and 1B1 in human blood lymphocytes are not suitable as biomarkers of exposure to dioxin-like compounds: polymorphisms and interindividual variation in expression and inducibility.Toxicol Sci. 2005 May;85(1):703-12. doi: 10.1093/toxsci/kfi089. Epub 2005 Jan 19. Toxicol Sci. 2005. PMID: 15659568
-
Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies.Mutat Res. 2003 Feb-Mar;523-524:173-82. doi: 10.1016/s0027-5107(02)00333-0. Mutat Res. 2003. PMID: 12628515 Review.
-
Inhibitors of cytochrome P450 (CYP) 1B1.Eur J Med Chem. 2017 Jul 28;135:296-306. doi: 10.1016/j.ejmech.2017.04.042. Epub 2017 Apr 18. Eur J Med Chem. 2017. PMID: 28458135 Review.
Cited by
-
Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.Arch Pharm Res. 2021 Jan;44(1):63-83. doi: 10.1007/s12272-021-01306-w. Epub 2021 Jan 23. Arch Pharm Res. 2021. PMID: 33484438 Review.
-
Potential role of CYP1B1 in the development and treatment of metabolic diseases.Pharmacol Ther. 2017 Oct;178:18-30. doi: 10.1016/j.pharmthera.2017.03.007. Epub 2017 Mar 16. Pharmacol Ther. 2017. PMID: 28322972 Free PMC article. Review.
-
Cancer Activation and Polymorphisms of Human Cytochrome P450 1B1.Toxicol Res. 2016 Apr;32(2):89-93. doi: 10.5487/TR.2016.32.2.089. Epub 2016 Apr 30. Toxicol Res. 2016. PMID: 27123158 Free PMC article. Review.
-
Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors.Bioinorg Chem Appl. 2018 Jul 25;2018:3924608. doi: 10.1155/2018/3924608. eCollection 2018. Bioinorg Chem Appl. 2018. PMID: 30147715 Free PMC article. Review.
-
Therapeutic Versatility of Resveratrol Derivatives.Nutrients. 2017 Oct 29;9(11):1188. doi: 10.3390/nu9111188. Nutrients. 2017. PMID: 29109374 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources